kr
44.80
May 3
Business Description
EQL Pharma AB
ISIN : SE0005497732
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.61 | |||||
Debt-to-EBITDA | 3.32 | |||||
Interest Coverage | 7.24 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.7 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 52.6 | |||||
3-Year EBITDA Growth Rate | 95.7 | |||||
3-Year EPS without NRI Growth Rate | 123.6 | |||||
3-Year Book Growth Rate | 24.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 13.06 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.84 | |||||
9-Day RSI | 71.93 | |||||
14-Day RSI | 68.54 | |||||
6-1 Month Momentum % | 56.25 | |||||
12-1 Month Momentum % | 23.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.28 | |||||
Quick Ratio | 0.56 | |||||
Cash Ratio | 0.08 | |||||
Days Inventory | 209.11 | |||||
Days Sales Outstanding | 82.65 | |||||
Days Payable | 84.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 1.03 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 45.34 | |||||
Operating Margin % | 12.2 | |||||
Net Margin % | 8.99 | |||||
FCF Margin % | -19.05 | |||||
ROE % | 13.72 | |||||
ROA % | 7.55 | |||||
ROIC % | 10.13 | |||||
ROC (Joel Greenblatt) % | 32.42 | |||||
ROCE % | 17.78 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 45.71 | |||||
PE Ratio without NRI | 45.71 | |||||
Shiller PE Ratio | 125.79 | |||||
PEG Ratio | 0.4 | |||||
PS Ratio | 5.37 | |||||
PB Ratio | 7.51 | |||||
Price-to-Tangible-Book | 186.67 | |||||
Price-to-Operating-Cash-Flow | 69.45 | |||||
EV-to-EBIT | 43.66 | |||||
EV-to-Forward-EBIT | 17.39 | |||||
EV-to-EBITDA | 43.66 | |||||
EV-to-Forward-EBITDA | 15.19 | |||||
EV-to-Revenue | 5.67 | |||||
EV-to-Forward-Revenue | 3.43 | |||||
EV-to-FCF | -28.86 | |||||
Price-to-Projected-FCF | 12.34 | |||||
Price-to-Median-PS-Value | 0.99 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.83 | |||||
Price-to-Graham-Number | 19.56 | |||||
Price-to-Net-Current-Asset-Value | 320 | |||||
Earnings Yield (Greenblatt) % | 2.29 | |||||
FCF Yield % | -3.6 | |||||
Forward Rate of Return (Yacktman) % | 19.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
EQL Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 246.367 | ||
EPS (TTM) (kr) | 0.98 | ||
Beta | 0.78 | ||
Volatility % | 39.83 | ||
14-Day RSI | 68.54 | ||
14-Day ATR (kr) | 1.375508 | ||
20-Day SMA (kr) | 43.41 | ||
12-1 Month Momentum % | 23.91 | ||
52-Week Range (kr) | 24.7 - 46 | ||
Shares Outstanding (Mil) | 29.06 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
EQL Pharma AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
EQL Pharma AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
EQL Pharma AB Frequently Asked Questions
What is EQL Pharma AB(XSAT:EQL)'s stock price today?
When is next earnings date of EQL Pharma AB(XSAT:EQL)?
Does EQL Pharma AB(XSAT:EQL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |